(Q34086098)

30 July 2017

1 reference

title

Risks and benefits of taxanes in breast and ovarian cancer (English)

1 reference

30 July 2017

1 reference

L B Michaud

1

1 reference

30 July 2017

V Valero

series ordinal

2

1 reference

30 July 2017

G Hortobagyi

series ordinal

3

1 reference

30 July 2017

1 November 2000

1 reference

30 July 2017

1 reference

30 July 2017

23

1 reference

30 July 2017

401-428

1 reference

30 July 2017

5

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200023050-00005

30 July 2017

0 references

cites work

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

1 reference

12 December 2020

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

1 reference

12 December 2020

A phase II trial and pharmacokinetic analysis of 96-hour infusional paclitaxel in patients with metastatic colorectal cancer

1 reference

12 December 2020

Hypersensitivity reactions from taxol

1 reference

12 December 2020

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer

1 reference

12 December 2020

Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer

1 reference

12 December 2020

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes

1 reference

12 December 2020

A phase I–II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer

1 reference

12 December 2020

Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs

1 reference

12 December 2020

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

12 December 2020

Polysorbate 80 hypersensitivity

1 reference

12 December 2020

Phase I and pharmacokinetic study of oral paclitaxel

1 reference

12 December 2020

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

1 reference

12 December 2020

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

12 December 2020

Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein

1 reference

12 December 2020

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer

1 reference

12 December 2020

Cytostatic and apoptotic effects of paclitaxel in human breast tumors

1 reference

12 December 2020

Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer

1 reference

12 December 2020

Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer

1 reference

12 December 2020

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

1 reference

12 December 2020

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

1 reference

12 December 2020

Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer

1 reference

12 December 2020

S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells

1 reference

12 December 2020

Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer

1 reference

12 December 2020

Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells

1 reference

12 December 2020

[Phase I study of paclitaxel]

1 reference

12 December 2020

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

1 reference

12 December 2020

Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel

1 reference

12 December 2020

Demonstration of the cell cycle positions of taxol-induced "asters" and "bundles" by sequential measurements of tubulin immunofluorescence, DNA content, and autoradiographic labeling of taxol-sensitive and -resistant cells.

1 reference

12 December 2020

Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew.

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of taxol.

1 reference

12 December 2020

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

12 December 2020

Cardiac disturbances during the administration of taxol

1 reference

12 December 2020

A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer

1 reference

12 December 2020

Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors

1 reference

12 December 2020

Sequences of taxol and cisplatin: a phase I and pharmacologic study

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel

1 reference

12 December 2020

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group

1 reference

12 December 2020

Typhlitis associated with docetaxel treatment

1 reference

12 December 2020

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

1 reference

12 December 2020

Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines.

1 reference

12 December 2020

Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.

1 reference

12 December 2020

Docetaxel in combination with doxorubicin: a phase I dose-finding study

1 reference

12 December 2020

Review of docetaxel/doxorubicin combination in metastatic breast cancer

1 reference

12 December 2020

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis

1 reference

12 December 2020

Development of polyploidization in taxol-resistant human leukemia cells in vitro.

1 reference

12 December 2020

Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs

1 reference

12 December 2020

Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet

1 reference

12 December 2020

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

1 reference

12 December 2020

Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion

1 reference

12 December 2020

Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.

1 reference

12 December 2020

Evaluation of the linearity of docetaxel pharmacokinetics.

1 reference

12 December 2020

Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer

1 reference

12 December 2020

Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26

1 reference

12 December 2020

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

1 reference

12 December 2020

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer

1 reference

12 December 2020

1 reference

12 December 2020

Activity of paclitaxel liposome formulations against human ovarian tumor xenografts

1 reference

12 December 2020

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients

1 reference

12 December 2020

Compounding an extended-stability admixture of Paclitaxel for long-term infusion

1 reference

12 December 2020

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

1 reference

12 December 2020

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol

1 reference

12 December 2020

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans

1 reference

12 December 2020

Successful re-treatment with taxol after major hypersensitivity reactions.

1 reference

12 December 2020

The taxoids. Comparative clinical pharmacology and therapeutic potential

1 reference

12 December 2020

Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer

1 reference

12 December 2020

Mechanisms of Taxol-induced cell death are concentration dependent.

1 reference

12 December 2020

An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.

1 reference

12 December 2020

Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms

1 reference

12 December 2020

Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly

1 reference

12 December 2020

Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.

1 reference

12 December 2020

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

12 December 2020

An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel

1 reference

12 December 2020

Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.

1 reference

12 December 2020

3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin

1 reference

12 December 2020

Taxol resistant mutants of Chinese hamster ovary cells: genetic biochemical, and cross-resistance studies.

1 reference

12 December 2020

Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over

1 reference

12 December 2020

Preclinical in vivo efficacy of two 9-dihydrotaxane analogues against human and murine tumours

1 reference

12 December 2020

Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences.

1 reference

12 December 2020

Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.

1 reference

12 December 2020

Tubulin polymerization by paclitaxel (taxol) phosphate prodrugs after metabolic activation with alkaline phosphatase

1 reference

12 December 2020

Docetaxel (taxotere, Rhone-Poulenc Rorer).

1 reference

12 December 2020

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

1 reference

12 December 2020

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

12 December 2020

Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind

1 reference

12 December 2020

The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer

1 reference

12 December 2020

A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine

1 reference

12 December 2020

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

1 reference

12 December 2020

Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer

1 reference

12 December 2020

Effects of Taxotere on murine and human tumor cell lines

1 reference

12 December 2020

Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol

1 reference

12 December 2020

Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer

1 reference

12 December 2020

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

1 reference

12 December 2020

Promotion of microtubule assembly in vitro by taxol

1 reference

12 December 2020

Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion

1 reference

12 December 2020

The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).

1 reference

12 December 2020

Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer

1 reference

12 December 2020

Mechanism of action of taxol

1 reference

12 December 2020

Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL

1 reference

12 December 2020

Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis

1 reference

12 December 2020

Paclitaxel rechallenge failure after a major hypersensitivity reaction

1 reference

12 December 2020

Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion

1 reference

12 December 2020

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

1 reference

12 December 2020

Infusion site soft-tissue injury after paclitaxel administration

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

12 December 2020

Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.

1 reference

12 December 2020

Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study

1 reference

12 December 2020

Phase I trial of Taxotere: five-day schedule

1 reference

12 December 2020

A phase I trial of taxol given by a 6-hour intravenous infusion

1 reference

12 December 2020

Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer

1 reference

12 December 2020

Solution structure of Taxotere-induced microtubules to 3-nm resolution. The change in protofilament number is linked to the binding of the taxol side chain

1 reference

12 December 2020

Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness

1 reference

12 December 2020

Paclitaxel (Taxol): phase I/II trial comparing 1-hour infusion schedules.

1 reference

12 December 2020

Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology

1 reference

12 December 2020

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer

1 reference

12 December 2020

10.2165/00002018-200023050-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference